MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious th...
Main Authors: | Peralta-Álvarez, MP, Downward, K, White, A, Redondo Azema, H, Sibley, L, Sarfas, C, Morrison, A, Dennis, M, Diaz-Santana, D, Harris, SA, Li, S, Puentes, E, Aguilo, N, Martin, C, Sharpe, S, McShane, H, Tanner, R |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
Nature Research
2024
|
Títulos similares
-
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
por: Marco Polo Peralta-Álvarez, et al.
Publicado: (2024-11-01) -
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
por: Marco Polo Peralta Alvarez, et al.
Publicado: (2024-05-01) -
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
por: Alvarez, MPP, et al.
Publicado: (2024) -
Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis
por: Alvaro Roy, et al.
Publicado: (2019-10-01) -
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
por: Harris, S, et al.
Publicado: (2017)